ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain

BACKGROUND: The present study aims to assess clinical and regulatory variables that would influence pricing and reimbursement (P&R) decisions for Orphan Drugs (ODs) in Spain. ODs approved by the European Commission (EC) between 2006 and 2021 were classified according to their P&R status in S...

Descripción completa

Detalles Bibliográficos
Autores principales: Poveda, José Luis, Gómez, Claudia, Gil, Alicia, Badia, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824902/
https://www.ncbi.nlm.nih.gov/pubmed/36609401
http://dx.doi.org/10.1186/s13023-022-02610-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824902/
https://www.ncbi.nlm.nih.gov/pubmed/36609401
http://dx.doi.org/10.1186/s13023-022-02610-4

Ejemplares similares